Cornering Cancer: Beyond Chemotherapy
Beyond Chemotherapy--How Treatment of Acute Myeloid Leukemia has Finally Evolved For over 30 years, the standard treatment for AML was a chemotherapy regimen called 7+3. Trial after trial of different chemotherapy combinations failed to improve outcomes. Now, in the last two years, nearly a dozen new drugs have been approved or are close to approval-most of which hit completely novel targets in a variety of different ways. This talk will cover what AML is and how our understanding of the disease at the molecular level has finally led to better, safer treatments available to more patients than ever before. The talk will also introduce some basic concepts of cancer biology which have been first learned in AML, but can also be extended to other cancers. Featuring: Dr. Peter Adams, Researcher at the Sanford Burnham Prebys Medical Discovery Institute, and Dr. Rafael Bejar, Clinician at UC San Diego.